Selected clinical trials in early-stage Hodgkin lymphoma without the use of novel agents
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Combined-modality treatment | ||||||||
| HD1013 | 1370 | Favorable, stage I or II | 38.8 | 1. ABVD × 4 + 30 Gy IFRT 2. ABVD × 4 + 20 Gy IFRT 3. ABVD × 2 + 30 Gy IFRT 4. ABVD × 2 + 20 Gy IFRT | 7.5 | CR rates 1. 96.3% 2. 96.6% 3. 97.3% 4. 96.3% | 8-year PFS 1. 88.4% 2. 90.0% 3. 85.4% 4. 86.5% | 8-year OS 1. 94.4% 2. 94.7% 3. 93.6% 4. 95.1% |
| HD1114 | 1395 | Unfavorable, stages IA, IB IIA, IIB | 33 | 1. ABVD × 4 + 30 Gy IFRT 2. ABVD × 4 + 20 Gy IFRT 3. BEACOPPbaseline × 4 + 30 Gy IFRT 4. BEACOPPbaseline × 4 + 20 Gy IFRT | 7.6 | CR rates Overall 94.1% 1. 94.7% 2. 92.8% 3. 94.4% 4. 94.6% | 5-year PFS 1. 87.2% 2. 82.1% 3. 87.9% 4. 87% | 5-year OS 1. 94.3% 2. 93.8% 3. 94.6% 4. 95.1% |
| HD1415 | 1528 | Unfavorable, stages IA, IB, IIA, IIB | 32 | 1. ABVD × 4 + 30 Gy IFRT 2. escBEACOPP × 4 + 30 Gy IFRT | 3.6 | CR rates Overall 95.4% | 5-year PFS 1. 89.1% 2. 95.4% | 5-year OS Overall 97.0% 1. 96.8% 2. 97.2% |
| PET-adapted treatment | ||||||||
| RAPID1 | 602 | Stage IA or IIA, nonbulky | 34 | ABVD × 3 → PET If PET–, then 1. IFRT or 2. No further treatment If PET+, then 3. ABVD × 1 + 30 Gy IFRT | 5 | 3-year PFS 1. 94.6% 2. 90.8% 3. 87.6% | 3-year OS 1. 97.1% 2. 99.0% 3. 87.6% | |
| CALGB 506043 | 164 | Stage I or II, favorable or unfavorable, nonbulky only | 31 | ABVD × 2 → PET 1. If PET–, then ABVD × 2 2. If PET+, then escBEACOPP× 2 + IFRT | 3.8 | EOT CR rate 1. 97% 2. 85% | 3-year PFS PET– DS 1-3 Overall 89% 1. 91% 2. 66% PET– DS 1-2 Overall 94% | |
| EORTC H102 | 1950 | Stage I or II, favorable or unfavorable | 30 | Favorable 1. ABVD × 2 → ABVD × 1 + INRT or ABVD × 2 → PET 2. If PET–, then ABVD × 2 3. If PET+, then escBEACOPP × 2 + INRT Unfavorable 4. ABVD × 2 → ABVD × 2 + INRT or ABVD × 2 → PET 5. If PET–, then ABVD × 4 6. If PET+, then escBEACOPP × 2 + INRT | 4.5 | PET+ Favorable and unfavorable Group 1 or 4: 5-year PFS 77.4% Group 3 or 6: 5-year PFS 90.6% PET– Favorable Group 1: 5-year PFS 99.0% Group 2: 5-year PFS 87.1% Unfavorable Group 4: 5-year PFS 92.1% Group 5: 5-year PFS 89.6% | PET+ Favorable and unfavorable Group 1 or 4: 5-year OS 89.3% Group 3 or 6: 5-year OS 96.0% PET– Favorable Group 1: 5-year OS 100% Group 2: 5-year OS 99.6% Unfavorable Group 4: 5-year OS 96.7% Group 5: 5-year OS 98.3% | |
| CALGB 5080148 | 94 | Stage IA-IIB, bulky only | 30 | ABVD × 2 → pET 1. PET–, then ABVD × 4 2. PET+, then escBEACOPP× 4 + 30 Gy ISRT | 5.5 | 3-year PFS 1. 89.7% 2. 92.3% | 3-year OS 1. 94.4% 2. 97.7% | |
| RATHL24 | 1203 | Stage IIB to IV or IIA with adverse features | 33 | ABVD × 2 → PET If PET–, then 1. ABVD × 4 or 2. AVD × 4 If PET+, then 3. BEACOPP × 4 | 3.4 | 3-year PFS 1. 85.7% 2. 84.4% 3. 67.5% | 3-year OS 1. 97.2% 2. 97.6% 3. 87.8% | |
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Combined-modality treatment | ||||||||
| HD1013 | 1370 | Favorable, stage I or II | 38.8 | 1. ABVD × 4 + 30 Gy IFRT 2. ABVD × 4 + 20 Gy IFRT 3. ABVD × 2 + 30 Gy IFRT 4. ABVD × 2 + 20 Gy IFRT | 7.5 | CR rates 1. 96.3% 2. 96.6% 3. 97.3% 4. 96.3% | 8-year PFS 1. 88.4% 2. 90.0% 3. 85.4% 4. 86.5% | 8-year OS 1. 94.4% 2. 94.7% 3. 93.6% 4. 95.1% |
| HD1114 | 1395 | Unfavorable, stages IA, IB IIA, IIB | 33 | 1. ABVD × 4 + 30 Gy IFRT 2. ABVD × 4 + 20 Gy IFRT 3. BEACOPPbaseline × 4 + 30 Gy IFRT 4. BEACOPPbaseline × 4 + 20 Gy IFRT | 7.6 | CR rates Overall 94.1% 1. 94.7% 2. 92.8% 3. 94.4% 4. 94.6% | 5-year PFS 1. 87.2% 2. 82.1% 3. 87.9% 4. 87% | 5-year OS 1. 94.3% 2. 93.8% 3. 94.6% 4. 95.1% |
| HD1415 | 1528 | Unfavorable, stages IA, IB, IIA, IIB | 32 | 1. ABVD × 4 + 30 Gy IFRT 2. escBEACOPP × 4 + 30 Gy IFRT | 3.6 | CR rates Overall 95.4% | 5-year PFS 1. 89.1% 2. 95.4% | 5-year OS Overall 97.0% 1. 96.8% 2. 97.2% |
| PET-adapted treatment | ||||||||
| RAPID1 | 602 | Stage IA or IIA, nonbulky | 34 | ABVD × 3 → PET If PET–, then 1. IFRT or 2. No further treatment If PET+, then 3. ABVD × 1 + 30 Gy IFRT | 5 | 3-year PFS 1. 94.6% 2. 90.8% 3. 87.6% | 3-year OS 1. 97.1% 2. 99.0% 3. 87.6% | |
| CALGB 506043 | 164 | Stage I or II, favorable or unfavorable, nonbulky only | 31 | ABVD × 2 → PET 1. If PET–, then ABVD × 2 2. If PET+, then escBEACOPP× 2 + IFRT | 3.8 | EOT CR rate 1. 97% 2. 85% | 3-year PFS PET– DS 1-3 Overall 89% 1. 91% 2. 66% PET– DS 1-2 Overall 94% | |
| EORTC H102 | 1950 | Stage I or II, favorable or unfavorable | 30 | Favorable 1. ABVD × 2 → ABVD × 1 + INRT or ABVD × 2 → PET 2. If PET–, then ABVD × 2 3. If PET+, then escBEACOPP × 2 + INRT Unfavorable 4. ABVD × 2 → ABVD × 2 + INRT or ABVD × 2 → PET 5. If PET–, then ABVD × 4 6. If PET+, then escBEACOPP × 2 + INRT | 4.5 | PET+ Favorable and unfavorable Group 1 or 4: 5-year PFS 77.4% Group 3 or 6: 5-year PFS 90.6% PET– Favorable Group 1: 5-year PFS 99.0% Group 2: 5-year PFS 87.1% Unfavorable Group 4: 5-year PFS 92.1% Group 5: 5-year PFS 89.6% | PET+ Favorable and unfavorable Group 1 or 4: 5-year OS 89.3% Group 3 or 6: 5-year OS 96.0% PET– Favorable Group 1: 5-year OS 100% Group 2: 5-year OS 99.6% Unfavorable Group 4: 5-year OS 96.7% Group 5: 5-year OS 98.3% | |
| CALGB 5080148 | 94 | Stage IA-IIB, bulky only | 30 | ABVD × 2 → pET 1. PET–, then ABVD × 4 2. PET+, then escBEACOPP× 4 + 30 Gy ISRT | 5.5 | 3-year PFS 1. 89.7% 2. 92.3% | 3-year OS 1. 94.4% 2. 97.7% | |
| RATHL24 | 1203 | Stage IIB to IV or IIA with adverse features | 33 | ABVD × 2 → PET If PET–, then 1. ABVD × 4 or 2. AVD × 4 If PET+, then 3. BEACOPP × 4 | 3.4 | 3-year PFS 1. 85.7% 2. 84.4% 3. 67.5% | 3-year OS 1. 97.2% 2. 97.6% 3. 87.8% | |
INRT, involved node radiotherapy; pET, positron emission tomography.